The Use of 5-Alpha Reductase Inhibitors to Manage Benign Prostatic Hyperplasia and the Risk of All-cause Mortality [PDF]
Urology, 2018 Ralph Horwitz +2 more
exaly +2 more sources
The connection of 5-alpha reductase inhibitors to the development of depression
Biomedicine & Pharmacotherapy, 2021 Recent literature connects 5-alpha reductase inhibitors (5-ARIs) with neuropsychiatric adverse effects. Several clinical studies have indicated that former 5-ARIs users had a higher incidence of depressive symptoms and neuropsychiatric side effects than non-users.
Thiraphat, Saengmearnuparp +3 more
openaire +2 more sources
Anatomic study of verumontanum during endoscopic surgeries in patients with benign prostatic hyperplasia [PDF]
International Brazilian Journal of Urology, 2021 Introduction and objective: To evaluate changes in verumontanum anatomy in patients with benign prostatic hyperplasia (BPH) who used 5-alpha reductase inhibitors (5-ARIs) and to propose an anatomical classification of the verumontanum.
Henrique Barbosa de Menezes +6 more
doaj +1 more source
Investigation of the Plausibility of 5-Alpha-Reductase Inhibitor Syndrome [PDF]
Skin Appendage Disorders, 2016 Postfinasteride syndrome (PFS) is a term recently coined to characterize a constellation of reported undesirable side effects described in postmarketing reports and small uncontrolled studies that developed during or after stopping finasteride treatment, and persisted after drug discontinuation. Symptoms included decreased libido, erectile dysfunction,
Raymond Fertig +3 more
openaire +2 more sources
Clinics, 2018 OBJECTIVES: To assess the associations between preoperative treatment with 5-alpha reductase inhibitors and the risks of blood transfusion during transurethral resection of the prostate and blood clot evacuation or emergency department visits for ...
Ti-Yuan Yang +6 more
doaj +1 more source
Effect of 5α-reductase inhibitors on the efficiency of thulium:yttrium-aluminium-garnet (RevoLix®) vaporesection for treating benign prostatic hyperplasia [PDF]
Investigative and Clinical Urology, 2020 Purpose: Preoperative use of 5α-reductase inhibitors (5ARIs) may cause fibrosis of the prostate tissue and reduce the efficiency of thulium laser surgery for treating benign prostate hyperplasia (BPH).
Jae Seung Chung +11 more
doaj +1 more source
5-Alpha Reductase Inhibitors and the Risk of Prostate Cancer Mortality in Men Treated for Benign Prostatic Hyperplasia [PDF]
Mayo Clinic Proceedings, 2016 Ralph Horwitz +2 more
exaly +2 more sources
Evaluation of Recent Trends in Treatment Patterns Among Men With Benign Prostatic Hyperplasia
American Journal of Men's Health, 2013 Although there is an abundance of evidence regarding clinical efficacy and safety of benign prostatic hyperplasia (BPH) treatment, real-world evidence is lacking for pharmacotherapy utilization and trends.
Eric J. Kruep PharmD, MS +2 more
doaj +1 more source
Antipsychotic-Like Properties of 5-α-Reductase Inhibitors [PDF]
Neuropsychopharmacology, 2008 Recent evidence indicates that neuroactive steroids may participate in the pathogenesis of schizophrenia spectrum disorders, yet the mechanisms of this involvement are elusive. As 5-alpha-reductase (5AR) is the rate-limiting enzyme of one of the two major metabolic pathways in brain steroidogenesis, we investigated the effects of its blockade in ...
Bortolato M +7 more
openaire +5 more sources
Effect of 5-alpha Reductase Inhibitor on Storage Symptoms in Patients with Benign Prostatic Hyperplasia [PDF]
International Neurourology Journal, 2011 Purpose Many patients with benign prostatic hyperplasia (BPH) have storage symptoms. The aim of this study was to evaluate the effects of treatment with a 5-alpha reductase inhibitor (5ARI) on storage symptoms in patients with BPH. Methods This study was
Kang Jun Cho +4 more
doaj +1 more source